Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Go back to Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
(NASDAQ: PPBT) Delayed: 1.43 +0.04 (2.88%)
Previous Close $1.39    52 Week High
Open $1.36    52 Week Low
Day High $1.51    P/E N/A 
Day Low $1.36    EPS
Volume 9,651       

(NASDAQ: PPBT) Delayed: 1.43 +0.04 (2.88%)
Previous Close $1.39    52 Week High
Open $1.36    52 Week Low
Day High $1.51    P/E N/A 
Day Low $1.36    EPS
Volume 9,651